Last reviewed · How we verify
Liposomal Amphotericin B
Liposomal amphotericin B binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and cause fungal cell death.
Liposomal amphotericin B binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and cause fungal cell death. Used for Invasive fungal infections (aspergillosis, candidiasis, cryptococcosis), Empiric therapy for presumed fungal infections in febrile neutropenic patients, Leishmaniasis.
At a glance
| Generic name | Liposomal Amphotericin B |
|---|---|
| Also known as | AmBisome, Ambisome, high dosage, Lipo-AB, LAMB |
| Sponsor | Taiwan Liposome Company |
| Drug class | Polyene antifungal |
| Target | Ergosterol |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amphotericin B is a polyene antibiotic that intercalates into ergosterol, a key sterol in fungal cell membranes, forming ion channels that lead to leakage of cellular contents and cell lysis. The liposomal formulation encapsulates the drug in lipid vesicles, which reduces systemic toxicity by preferentially delivering amphotericin B to infected tissues while minimizing exposure to human cell membranes that contain cholesterol rather than ergosterol.
Approved indications
- Invasive fungal infections (aspergillosis, candidiasis, cryptococcosis)
- Empiric therapy for presumed fungal infections in febrile neutropenic patients
- Leishmaniasis
Common side effects
- Nephrotoxicity (elevated creatinine)
- Infusion-related reactions (fever, chills, rigors)
- Hypokalemia
- Anemia
- Hypomagnesemia
Key clinical trials
- Human Bioequivalence Study of Liposomal Amphotericin B for Injection (NA)
- Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) (PHASE3)
- Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment (PHASE2)
- Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT) (PHASE3)
- Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections (PHASE2)
- A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
- Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction (NA)
- Platform Trial For Cryptococcal Meningitis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposomal Amphotericin B CI brief — competitive landscape report
- Liposomal Amphotericin B updates RSS · CI watch RSS
- Taiwan Liposome Company portfolio CI